CD19t T-APC

CD19t T-APC (CD19t T-antigen presenting cells) is a cell therapy product consisting of autologous T-cells that have been genetically modified to express a truncated human CD19 (CD19t) antigen. This investigational therapy is designed to enhance the persistence and activity of CD19-specific Chimeric Antigen Receptor (CAR) T-cells in patients with CD19-positive B-cell malignancies, particularly acute lymphoblastic leukemia. By providing episodic antigen stimulation, CD19t T-APCs aim to trigger the proliferation and re-activation of CAR T-cells in vivo, thereby improving the durability of remission and potentially reducing relapse rates after CAR T-cell therapy. It is administered intravenously following CAR T-cell infusion and chemotherapy.

Other names

CD19t T-antigen presenting cellsCD-19t T-antigen presenting cellsCD 19t T-antigen presenting cellsT-APCs